Tepylute Dosage

Recommended Dosage

Adenocarcinoma of the Breast or Ovary

The recommended dose of TEPYLUTE for treatment of adenocarcinoma of the breast or ovary is 0.3 mg/kg to 0.4 mg/kg intravenously. Doses should be given at 1 to 4 week intervals. Initially the higher dose in the given range is commonly administered. The maintenance dose should be adjusted weekly on the basis of pretreatment control blood counts and subsequent blood counts.

Maintenance doses should not be administered more frequently than weekly.

Preparation Instructions

TEPYLUTE is a hazardous drug. Follow applicable special handling and disposal procedures1.

​Use aseptic technique to prepare TEPYLUTE.

Dilution in the infusion bag

• Remove vial from refrigerated conditions 1 hour prior to dilution.
• ​Dilute the solution in an appropriate volume of 0.9% Sodium Chloride Injection to obtain a final TEPYLUTE concentration between 0.5 mg/mL and 1 mg/mL. Use a 16G needle with a Luer-lock syringe to dilute the solution.
• Use the diluted TEPYLUTE infusion solution immediately. If the solution is not used immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours, or at room temperature 25°C (77°F) for up to 4 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use TEPYLUTE diluted solutions only if free of visible particulate matter. Filter using a 0.2 micron filter prior to administration. Filtering does not alter solution potency.

​Storage of Undiluted TEPYLUTE:

• ​Single-dose vial: Each vial is intended for single-dose only. Discard any unused portion left in the vial.
• ​Multiple-dose vial: After first use, store the partially used vial in the original carton refrigerated at 2°C to 8°C (36°F to 46°F) for 14 days.